<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Hypermethylation of secreted frizzled-related proteins (SFRP) genes frequently occurs with several <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> but has not been studied in esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> or its precursor-<z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>To explore the role of SFRP methylation in the <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">neoplastic progression</z:e> of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> and to evaluate methylated SFRP genes as biomarkers for <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, methylation of SFRP genes was determined in esophageal <z:mp ids='MP_0009308'>adenocarcinomas</z:mp>, <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> and <z:mpath ids='MPATH_458'>normal</z:mpath> epithelia using methylation-specific PCR </plain></SENT>
<SENT sid="2" pm="."><plain>Protein expression of SFRP genes was then assessed in these tissues by immunohistochemistry </plain></SENT>
<SENT sid="3" pm="."><plain>The <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression of SFRP genes was quantified by real-time reverse-transcription PCR in esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> cell lines with and without demethylation by <z:chebi fb="0" ids="50131">5-aza-2'deoxycytidine</z:chebi> and inhibition of deacetylation by <z:chebi fb="0" ids="46024">trichostatin A</z:chebi> treatment </plain></SENT>
<SENT sid="4" pm="."><plain>Hypermethylation of SFRP1, 2, 4 and 5 was detected in 93%, 83%, 73% and 85% of 40 cancers; 81%, 89%, 78% and 73% of 37 Barrett's epithelia; 25%, 64%, 32% and 21% of 28 adjacent <z:mpath ids='MPATH_458'>normal</z:mpath> epithelia from Barrett's patients; and 10%, 67%, 0% and 13% of 30 <z:mpath ids='MPATH_458'>normal</z:mpath> esophagogastric epithelia from healthy individuals, respectively (p &lt; 0.001 for SFRP1, 4 and 5; p &lt; 0.05 for SFRP2) </plain></SENT>
<SENT sid="5" pm="."><plain>Protein expression of SFRP1, 2 and 4 was downregulated in 87%, 67% and 90% of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, and expression correlated inversely with grade and stage of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> and with grade of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> </plain></SENT>
<SENT sid="6" pm="."><plain>Expression of SFRP2 and SFRP4 proteins was lower in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> with corresponding gene methylation (p &lt; 0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>Demethylation treatment effectively re-expressed SFRP <z:chebi fb="2" ids="33699">mRNA</z:chebi> in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell lines </plain></SENT>
<SENT sid="8" pm="."><plain>Thus, hypermethylation of SFRP genes is a common early event in the evolution of esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, and methylation of SFRP1, 4 and 5 might serve as biomarkers for Barrett's <z:hpo ids='HP_0002664'>neoplasia</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Aberrant promoter methylation appears to functionally silence SFRP gene expression in esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
</text></document>